Changes to Model Assumptions of the Cost-effectiveness of Durvalumab Therapy for Non-Small Cell Lung Cancer

JAMA Oncol. 2019 Jul 1;5(7):1066. doi: 10.1001/jamaoncol.2019.1088.

Authors

Smith Giri^{1

2}, Scott F Huntington^{1

2}

Affiliations

¹ Section of Hematology, Department of Internal Medicine, Yale University, New Haven, Connecticut.
² Cancer Outcomes, Public Policy, and Effectiveness Research Center, Yale University, New Haven, Connecticut.

PMID: 31095252
DOI: 10.1001/jamaoncol.2019.1088

No abstract available

Publication types

Comment

MeSH terms

Antibodies, Monoclonal
Carcinoma, Non-Small-Cell Lung*
Chemoradiotherapy
Consolidation Chemotherapy
Cost-Benefit Analysis
Humans
Lung Neoplasms*

Substances

Antibodies, Monoclonal
durvalumab